FGF23 is putative factor in the fragility of CKD-MBD, less so in age-related bone loss; future elucidation of pathogenesis requires remodelling biomarkers, while gender differences need elucidation with respect to abnormal bone mineral homeostasis and reduced BMD as part of a future model of fragility risk factors. The gene discussed is FGF23; the disease is chronic kidney disease.